Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X:
“Can ctDNA change clinical practice in bladder cancer?
After cystectomy
- ctDNA (+) ━ very high recurrence risk
- ctDNA (−) ━ favorable prognosis may influence adjuvant treatment decisions (especially for immunotherapy)
During neoadjuvant therapy
- ctDNA persistence ━ chemoresistance
- ctDNA clearance ━ better clinical outcomes
In addition
- ctDNA ━ reveals tumor-specific mutations → provides insight into treatment selection and resistance mechanisms
My perspective:
In early-stage bladder cancer, ctDNA appears ready to be integrated across neoadjuvant, adjuvant, and surveillance settings”
Title: Blood and Urine Circulating Tumor DNA in Urothelial Bladder Cancer: State of the Art and Clinical Perspective
Authors: Igor Duquesne, Isabelle Epelbaum, Doriane Prost, Mathilde Haberstich, Caio Vinícius Suartz, Hélène Blons, Valérie Taly, Pierre Laurent-Puig, Amir Horowitz, John P. Sfakianos, Constance Thibault, François Audenet.
Other articles featuring Ahmet Dirican on OncoDaily.